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A B S T R A C T
In myasthenia gravis (MG) patients without detectable anti-acetylcholine receptor (anti-AChR) antibody, referred to
as seronegative myasthenia gravis patients, there is a variable proportion of patients with antibodies against the mus-
cle-specific kinase (MuSK). MuSK antibodies were found in 8 (29.6%) of our 27 patients with generalized MG without
anti-AChR antibodies. All these patients were female. The age at the onset ranged from 22 to 38 years. All patients had
ocular and bulbar symptoms, and two patients also had generalized limb weakness. Two patients had pure ocular symp-
toms for 7 or 8 years before the development of bulbar symptoms. All anti-MuSK positive patients were treated with
immunosuppressive drugs, three received plasmapheresis and one patient required mechanical ventilation. Our results
are consistent with other literature reports.
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Introduction
Myasthenia gravis (MG) is an autoimmune disease af-
fecting neuromuscular junction, which results in impair-
ment of neuromuscular transmission with clinical featu-
res of weakness and fatigue. Autoantibodies to acetylcho-
line receptors in serum are detected in 80%–90% of pa-
tients with generalized MG (AChR-MG)1. AChR antibod-
ies reduce the number of avaliable postsynaptic AChRs.
About 10%–20% of patients with generalized MG do not
have antibodies to AChR and they are referred to as
seronegative MG (SNMG) patients. However, a number
of these patients (22%–70%) have antibodies against the
muscle-specific kinase (MuSK, MuSK-MG)2–13.. Interest-
ingly, in Norway no such patient had been identified be-
fore 200514.
We report on our patients with anti-MuSK antibodies,
with special reference to their clinical characteristics.
Patients and Methods
We present eight seronegative MG patients with posi-
tive anti-MuSK antibodies, treated at Department of Neu-
romuscular Diseases, Department of Neurology, Univer-
sity Hospital Center Zagreb in Zagreb. The diagnosis of
MG was based on clinical recognition of typical myas-
thenic symptoms with diurnal variation and pharmaco-
logical testing (acetylcholinesterase inhibitor injection).
Electrophysiological study (repetitive nerve stimula-
tion) was performed in six patients. Three patients had
mildly positive test, whereas three patients had normal
findings.
The anti-AChR antibodies were testing using stan-
dard radioimmunoassay of serum samples, with values
below 0.2 nmol/L considered negative. The anti-MuSK
antibodies were tested using standard radioimmunoas-
say of serum samples in Oxford, UK (Professor Angela
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Vincent, Neurosciences Group, Institute of Molecular
Medicine, John Radcliffe Hospital, Oxford University).
Testing for antibodies was performed from June 2005 to
October 2007.
Results
Anti-MuSK antibodies were present in eight (29.6%)
of 27 patients with anti-AChR-antibody-negative MG.
None of the patients with anti-AChR antibodies had
anti-MuSK antibodies. All MuSK positive patients were
women. The age at onset ranged from 22 to 39 years. De-
mographic and clinical characteristics of MG patients
with positive anti-MuSK antibodies are shown in Table
1. All patients were treated with pyridostigmine, with
minimal response in two patients. Immunosuppressive
drugs were added according to current indications in all
patients and proved efficacious. All anti-MuSK positive
patients were treated with immunosuppressants, three
received plasmapheresis and one patient required me-
chanical ventilation at the onset of MG. All patients had
ocular and bulbar symptoms, and two patients also sho-
wed symptoms of generalized MG. Two patients had pure
ocular symptoms for 7 or 8 years before the occurrence of
bulbar symptoms.
One patients suffering from chronic MG for 33 years
had overt hypotrophy of limb muscles. Muscle atrophy
was not observed in other patients.
Discussion
Hoch et al. found antibodies to a membrane-linked
muscle-specific kinase in sera of 17 of 24 patients with
seronegative MG2. MuSK is a transmembrane polypepti-
de expressed in skeletal muscle localized predominantly
on the postsynaptic membrane of the neuromuscular
junction. Although MuSK is very important in muscle
development, its role in mature muscles has not yet been
fully clarified. Antibodies to MuSK have been identified
in sera of 22–70% of seronegative MG patients2–13, but
not in sera with positive AChR antibodies. In Norway,
none had been identified before 200514. Clinically, it was
soon recognized that the absence of anti-AChR antibod-
ies did not necessarily mean mild disease. Severe symp-
toms requiring immunosuppressive therapy are reported
to be similar, or may even be more frequent, in patients
with anti-MuSK antibodies. While their main clinical
characteristic, muscle fatique, is similar to those in pa-
tients with anti-AChR antibodies, their weakness more
commonly and more severely involves oculobulbar, neck
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TABLE 1
DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF PATIENTS WITH ANTI-MuSK POSITIVE MYASTHENIA GRAVIS
Patient No.
Sex
Year of birth
Age at on-
set (yrs)
Duration (yrs)
to the last
follow up
Symptoms to the last
follow up
Therapy
Pyridostigmine +
Thymectomy
– thymus
Follow up
1
F
1976
24 7
Ocular,
bulbar/speech
Corticosteroids
Plasmapheresis
– Periodical exacerbation
2
F
1970
32 5 Bulbar
Corticosteroids
periodically
+ »normal«
thymus
Improvement
post-thymectomy,
stable remission
3
F
1954
20 33
Ocular at onset,
bulbar, limb weakness
Corticosteroids
+ No data
on thymus
Chronic disease with limb
and bulbar weakness;
hypotrophy of limb muscles
4
F
1949
39 18
Ocular, bulbar,
respiratory weakness
Corticosteroids –
Acute onset with bulbar and
respiratory symptoms need-
ing assisted ventilation; later,
two episodes of exacerbation
with bulbar symptoms; now
stable for 5 yrs
5
F
1973
22 12 Ocular, bulbar
Corticosteroids
Azathioprine
Plasmapheresis
–
Ocular symptoms for 8 yrs;
periodically bulbar symptoms
in the last 4 yrs
6
F
1976
24 7
Bulbar, ocular,
generalized weakness
Corticosteroids
Azathioprine
Plasmapheresis
–
Periodical exacerbation
(stress)
7
F
1955
32 20 Ocular, bulbar Corticosteroids –
Stable improvement with
low steroid dose
8
F
1959
38 10
Ocular, bulbar,
neck muscles
Corticosteroids –
Periodically pure ocular
symptoms; in 2005 and 2007,
bulbar and neck weakness
and respiratory muscles, and respiratory crises are also
more common. Several clinical studies on MuSK-MG
have been published, showing that this MG subset has a
clearly clinical pattern3–6,8–13..
Evoli et al. have described clinical phenotype in 37 pa-
tients with positive MuSK antibodies. In their study, fe-
male patients predominated (n=29). Age at onset ranged
from 6 to 68 years, with 56.8% of patients presenting be-
low 40 years of age3.
Sanders et al. describe clinical aspects in 12 (38%) of
32 seronegative MG patients with disease onset at age
21–59. The response to acetylcholinesterase inhibitors was
variable. All patients improved after plasmapheresis, and
most had good response to immunosuppressive therapy8.
Zhou et al. compared clinical findings of patients with
positive MuSK antibodies and other seronegative pa-
tients. They noticed that neck muscles were commonly
involved in anti-MuSK positive patients and limb mus-
cles in seronegative patients (without AChR or MuSK
antibodies). The responses to anti-cholinesterase and
immunosuppressive treatment were similar9. Lavrnic et
al. found the majority of patients with anti-MuSK anti-
bodies to have predominant involvement of facial and
bulbar muscles (82.4% of 17 patients). There was also a
high prevalence of female patients (15 of 17). One third of
them did not respond well to anti-cholinesterase drugs5.
Our group of patients with anti-MuSK antibodies was
characterized by high prevalence of female patients with
age at onset of MG ranging from 23 to 28 years. This
finding was consistent with literature data. Approxi-
mately 50% of patients with ocular MG have anti-AChR
antibodies. Anti-MuSK antibodies are very rarely pres-
ent in pure ocular MG, although most patients first pres-
ent with mainly ocular symptoms15. Indeed, two of our
patients had pure ocular symptoms for 7 or 8 years be-
fore the development of bulbar symptoms. Interestingly,
however, Ishii et al. report on a patient with anti-MuSK
positive MG that showed progressive muscular atrophy
and weakness in bulbar region and upper extremities
without ptosis during 22-year clinical course16. One of
our patients suffering from MG for 33 years had hypo-
trophy of limb muscles.
There is no clear evidence for the efficacy of thy-
mectomy in anti-MuSK positive patients, possibly be-
cause only few patients have been thymectomized3,6–11.
Similarly, in our study, we could not make any definite
conclusion on the clinical benefits of thymectomy be-
cause only two of our patients were thymectomized and
one of them reached stable remission. The histopatho-
logic finding in this patient was »normal« thymus. The
other thymectomized patient had undergone thymectomy
30 years before and no relevant data on the histopatho-
logic finding in thymus tissue were available. More pro-
spective controlled studies will hopefully shed more light
on the issue in the future.
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MIASTENIJA GRAVIS KOD BOLESNIKA S POZITIVNIM PROTUTIJELIMA NA MuSK
S A @ E T A K
Bolesnici s miastenijom gravis (MG) kod kojih se ne na|u protutijela na acetilkolinske receptore (AChR) referiraju
se kao bolesnici sa seronegativnommiastenijom gravis. Ti bolesnici u razli~itom postotku imaju pozitivna protutijela na
specifi~nu mi{i}nu kinazu (MuSK). Protutijela na MuSK bila su pozitivna kod 8 od 27 na{ih bolesnika s MG (29,6%)
kod kojih nisu na|ena protutijela na AChR. Svi na{i bolesnici su bile `ene. Simptomi MG su se javili u dobi od 22–38
godina. Sve bolesnice su imale o~ne i bulbarne simptome, a dvije su imale i generaliziranu slabost u rukama i nogama.
Dvije su bolesnice imale samo okularne simptome 7 odnosno 8 godina prije pojave bulbarnih simptoma. Sve su lije~ene
imunosupresivnom terapijom, tri su bolesnice lije~ene plazmaferezom, a jedna je u jednom razdoblju trebala i meha-
ni~ku ventilaciju. Na{i rezultati su sli~ni rezultatima ostalih autora.
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